Displaying drugs 10851 - 10875 of 11604 in total
V591
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … vaccine virus as a vector for COVID-19 antigen delivery[L30593]. ... The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... MB07811, a small molecule that is administered orally, has been extensively studied preclinically and ... MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting …
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a ... pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a ... These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, …
GFT14
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous …
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Sulfatide
Any of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers and may accumulate in metachromatic leukodystrophy.
Experimental
Matched Description: … Any of a class of cerebroside sulfuric esters, they are found largely in the medullated nerve fibers …
Lemuteporfin
Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
Investigational
Matched Description: … Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer …
Fontolizumab
Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Investigational
Matched Description: … Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used …
TP-508
TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Investigational
Matched Description: … TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified …
Hydracarbazine
Hydracarbazine is a pyridazine that has found use as an antihypertensive agent It was once marketed in France under the tradename Normatensyl.
Experimental
Matched Description: … Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed …
Robenacoxib
Robenacoxib is a non-steroidal anti-inflammatory drug used in veterinary medicine for the relief of pain and inflammation in cats and dogs.
Experimental
Vet approved
Matched Description: … Robenacoxib is a non-steroidal anti-inflammatory drug used in veterinary medicine for the relief of pain …
Imidocarb
Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.
Vet approved
Matched Description: … Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment …
Trametes versicolor fruiting body
Trametes versicolor fruiting body is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Trametes versicolor fruiting body is a plant/plant extract used in some OTC (over-the-counter) products …
Magnolia kobus flowering top
Magnolia kobus flowering top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Magnolia kobus flowering top is a plant/plant extract used in some OTC (over-the-counter) products. …
Chamaecyparis obtusa wood oil
Chamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Chamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. …
Chlorotoxin
Chlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).
Investigational
Matched Description: … Chlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous …
REC-994
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Investigational
Matched Description: … REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous …
Levophencynonate
Levophencynonate is under investigation in clinical trial NCT02299804 (A Clinical Trial to Evaluate Efficacy and Safety of Levophencynonate Hydrochloride in Patient With Vertigo).
Investigational
Matched Description: … Levophencynonate is under investigation in clinical trial NCT02299804 (A Clinical Trial to Evaluate Efficacy …
Orticumab
Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors).
Investigational
Matched Description: … Orticumab is under investigation in clinical trial NCT04776629 (A Proof-of-activity Study With Orticumab …
CAR BCMA-CS1
CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.
Investigational
Matched Description: … CAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target …
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
PBGM01
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
Matched Description: … PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human …
1D09C3
1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC class II-positive tumor cells, which include...
Investigational
Matched Description: … 1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex ... B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a …
CR665
CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid receptor agonists. In preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound. In addition, unlike currently marketed opioids, CR665 does...
Investigational
Matched Description: … Preclinical animal studies suggest that CR665 is a potent analgesic compound. ... CR665 is the lead clinical development candidate from a series of highly selective peripheral kappa opioid …
Displaying drugs 10851 - 10875 of 11604 in total